Oragenics (NYSE:OGEN) Coverage Initiated by Analysts at StockNews.com

Analysts at StockNews.com began coverage on shares of Oragenics (NYSE:OGENGet Rating) in a research report issued to clients and investors on Monday. The brokerage set a “hold” rating on the stock.

Oragenics Price Performance

Shares of Oragenics stock opened at $0.20 on Monday. Oragenics has a fifty-two week low of $0.19 and a fifty-two week high of $0.63. The firm has a market cap of $23.46 million, a P/E ratio of -1.54 and a beta of 0.24. The firm has a 50 day simple moving average of $0.23 and a 200 day simple moving average of $0.29.

Oragenics Company Profile

(Get Rating)

Oragenics, Inc develops antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus; and Terra CoV-2, an intramuscular vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.

Featured Articles

Receive News & Ratings for Oragenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oragenics and related companies with MarketBeat.com's FREE daily email newsletter.